News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/antihemophilic_factor.jpg)
Hemophilia B drug available in larger vial
- Author:
- HT Staff
CSL Behring has announced that Idelvion (Coagulation Factor IX [Recombinant], Albumin Fusion Protein) is now available in a 3500 IU vial size....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vincent-ben-UNC-220.jpg)
Team identifies potential immunotherapy target for AML
- Author:
- HT Staff
New research could aid the development of immunotherapies tailored to patients with acute myeloid leukemia (AML) who are undergoing stem cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/GVHD_skin_biopsy_showing_Credit_PLOS_ONE_230.jpg)
Mechanism of cGVHD response to ECP still unclear
- Author:
- HT Staff
A prospective study did not reveal the mechanism driving response to extracorporeal photopheresis (ECP) in patients with chronic graft-versus-host...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ALL-B-cell_240.jpg)
First CAR T-cell therapy approved in Canada
- Author:
- HT Staff
Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/kymriah-tisagenlecleucel-ctl019-novartis-230.jpg)
CAR T-cell therapy will soon be available in England, NHS says
- Author:
- HT Staff
The National Health Service (NHS) of England has announced that tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy,...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/HSCs_in_bone_marrow_230.jpg)
Humans may have more HSCs than we thought
- Author:
- HT Staff
Humans may have ten times more hematopoietic stem cells (HSCs) than previously thought, according to research published in Nature. Researchers...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ALCL-MichaelBonert-230.jpg)
TYK2 inhibitors could treat ALCL, team says
- Author:
- HT Staff
Preclinical research indicates that TYK2 inhibitors could be effective in treating anaplastic large-cell lymphoma (ALCL). Researchers found...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/sickle_cell_and_normal_RBC_Credit_Betty_Pace_220.jpg)
Research may help explain how VOCs occur
- Author:
- HT Staff
Researchers say they have gained new insight that may help explain how vaso-occlusive crises (VOCs) occur in patients with sickle cell disease (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/researchers_woman_micro_man_standing_Rhoda_Baer_230.jpg)
Study authors fail to disclose industry payments
- Author:
- HT Staff
New research suggests investigators involved in oncology trials sometimes fail to disclose payments from the pharmaceutical industry. Researchers...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials-syringe-240.png)
Caplacizumab approved to treat aTTP
- Author:
- HT Staff
The European Commission has granted marketing authorization for caplacizumab (Cablivi™), a humanized bivalent nanobody that inhibits the...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/DARZALEX-daratumumab-400mg-230.jpg)
Daratumumab approved for new indication in MM
- Author:
- HT Staff
The European Commission (EC) has approved a new indication for daratumumab (Darzalex®). The drug is now authorized for use in combination with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/jivi_bayer-210.jpg)
Factor VIII product approved for hemophilia A
- Author:
- HT Staff
The US Food and Drug Administration (FDA) has approved Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) for the treatment of hemophilia...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/AML_cells_Credit_Lance_Liotta_230.jpg)
PLK1 inhibitor receives orphan designation for AML
- Author:
- HT Staff
The European Commission has granted orphan drug designation to onvansertib for the treatment of acute myeloid leukemia (AML). Onvansertib (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Hemlibra_emicizumab-businesswire-230.jpg)
A new standard of care in hemophilia A?
- Author:
- HT Staff
Results of a phase 3 trial showed that prophylaxis with emicizumab significantly reduced bleeds, compared to no prophylaxis, in patients with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/blinatumomab-vials-blincyto-amgen-220.jpg)
EC approves blinatumomab for kids
- Author:
- HT Staff
The European Commission (EC) has expanded the approved indication for blinatumomab (Blincyto®), a bispecific, CD19-directed, CD3 T-cell engager...